Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Adherens junction 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
2 Adipocytokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
3 Adipocytokine signaling pathway 💬
 1件: LEPR 💬 D05014 💬 Metreleptin 1件: 265 💬
4 Adipocytokine signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
5 Adipocytokine signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
7 Alcoholic liver disease 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
8 Alcoholic liver disease 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
9 Alcoholism 💬
 1件: ADORA2A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
10 Alcoholism 💬
 1件: ADORA2A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
11 Aldosterone synthesis and secretion 💬
 1件: PDE2A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
12 Aldosterone synthesis and secretion 💬
 1件: PDE2A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
13 AMPK signaling pathway 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
14 AMPK signaling pathway 💬
 1件: HMGCR 💬 D08410 💬 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 💬
15 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
16 AMPK signaling pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
17 AMPK signaling pathway 💬
 1件: LEPR 💬 D05014 💬 Metreleptin 1件: 265 💬
18 AMPK signaling pathway 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
19 AMPK signaling pathway 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
20 AMPK signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
21 Apelin signaling pathway 💬
 1件: PDE3B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
22 Apelin signaling pathway 💬
 1件: PDE3B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
23 Apelin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
24 Autophagy - animal 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
25 Autophagy - animal 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
26 Bile secretion 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
27 Bile secretion 💬
 1件: HMGCR 💬 D08410 💬 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 💬
28 Bile secretion 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
29 Bile secretion 💬
 1件: NR1H4 💬 D10699 💬 Cholic Acid 4件: 20, 234, 265, 310 💬
30 Bile secretion 💬
 1件: NR1H4 💬 D09360 💬 Obeticholic acid 3件: 93, 265, 296 💬
31 Breast cancer 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
32 Calcium signaling pathway 💬
 2件: ADORA2A, PDE1B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
33 Calcium signaling pathway 💬
 2件: ADORA2A, PDE1B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
34 cAMP signaling pathway 💬
 8件: ADORA1, ADORA2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
35 cAMP signaling pathway 💬
 8件: ADORA1, ADORA2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
36 cAMP signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
37 cGMP-PKG signaling pathway 💬
 5件: ADORA1, PDE2A, PDE3A, PDE3B, PDE5A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
38 cGMP-PKG signaling pathway 💬
 5件: ADORA1, PDE2A, PDE3A, PDE3B, PDE5A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
39 Chemical carcinogenesis - receptor activation 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
40 Chemical carcinogenesis - receptor activation 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
41 Chemokine signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
42 Cholesterol metabolism 💬
 1件: APOC3 💬 D11648 💬 Volanesorsen 1件: 265 💬
43 Cholinergic synapse 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
44 Circadian rhythm 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
45 Coronavirus disease - COVID-19 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
46 Cytokine-cytokine receptor interaction 💬
 1件: GHR 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
47 Cytokine-cytokine receptor interaction 💬
 1件: GHR 💬 D05394 💬 Pegvisomant 2件: 78, 265 💬
48 Cytokine-cytokine receptor interaction 💬
 1件: LEPR 💬 D05014 💬 Metreleptin 1件: 265 💬
49 Diabetic cardiomyopathy 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
50 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
51 EGFR tyrosine kinase inhibitor resistance 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
52 Endocrine resistance 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
53 Endocytosis 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
54 Epstein-Barr virus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
55 Fluid shear stress and atherosclerosis 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
56 Focal adhesion 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
57 FoxO signaling pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
58 FoxO signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
59 Glioma 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
60 Glucagon signaling pathway 💬
 1件: PDE3B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
61 Glucagon signaling pathway 💬
 1件: PDE3B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
62 Glucagon signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
63 Glucagon signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
64 Growth hormone synthesis, secretion and action 💬
 1件: GHR 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
65 Growth hormone synthesis, secretion and action 💬
 1件: GHR 💬 D05394 💬 Pegvisomant 2件: 78, 265 💬
66 Growth hormone synthesis, secretion and action 💬
 1件: GHRHR 💬 D06655 💬 Tesamorelin 2件: 78, 265 💬
67 Growth hormone synthesis, secretion and action 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
68 Hepatitis B 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
69 Hepatitis C 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
70 Hepatitis C 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
71 Hepatocellular carcinoma 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
72 Herpes simplex virus 1 infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
73 HIF-1 signaling pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
74 Human cytomegalovirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
75 Human papillomavirus infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
76 Human T-cell leukemia virus 1 infection 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
77 Huntington disease 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
78 Huntington disease 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
79 Hypertrophic cardiomyopathy 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
80 Influenza A 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
81 Insulin resistance 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
82 Insulin resistance 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
83 Insulin signaling pathway 💬
 1件: PDE3B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
84 Insulin signaling pathway 💬
 1件: PDE3B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
85 Insulin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
86 JAK-STAT signaling pathway 💬
 1件: GHR 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
87 JAK-STAT signaling pathway 💬
 1件: GHR 💬 D05394 💬 Pegvisomant 2件: 78, 265 💬
88 JAK-STAT signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
89 JAK-STAT signaling pathway 💬
 1件: LEPR 💬 D05014 💬 Metreleptin 1件: 265 💬
90 Kaposi sarcoma-associated herpesvirus infection 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
91 Leishmaniasis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
92 Lipid and atherosclerosis 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
93 Lipid and atherosclerosis 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
94 Lipid and atherosclerosis 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
95 Long-term depression 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
96 Longevity regulating pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
97 Longevity regulating pathway 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
98 Longevity regulating pathway 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
99 Longevity regulating pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
100 Longevity regulating pathway - multiple species 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
101 Longevity regulating pathway - multiple species 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
102 MAPK signaling pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
103 Measles 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
104 Melanoma 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
105 Metabolic pathways 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
106 Metabolic pathways 💬
 1件: HMGCR 💬 D08410 💬 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 💬
107 Metabolic pathways 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
108 Metabolic pathways 💬
 9件: PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
109 Metabolic pathways 💬
 9件: PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
110 Morphine addiction 💬
 9件: ADORA1, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
111 Morphine addiction 💬
 9件: ADORA1, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
112 mTOR signaling pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
113 mTOR signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
114 Necroptosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
115 Neuroactive ligand-receptor interaction 💬
 2件: ADORA1, ADORA2A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
116 Neuroactive ligand-receptor interaction 💬
 2件: ADORA1, ADORA2A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
117 Neuroactive ligand-receptor interaction 💬
 1件: GHR 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
118 Neuroactive ligand-receptor interaction 💬
 1件: GHR 💬 D05394 💬 Pegvisomant 2件: 78, 265 💬
119 Neuroactive ligand-receptor interaction 💬
 1件: GHRHR 💬 D06655 💬 Tesamorelin 2件: 78, 265 💬
120 Neuroactive ligand-receptor interaction 💬
 1件: LEPR 💬 D05014 💬 Metreleptin 1件: 265 💬
121 Neuroactive ligand-receptor interaction 💬
 1件: MC4R 💬 D11927 💬 Setmelanotide 2件: 202, 265 💬
122 NOD-like receptor signaling pathway 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
123 Non-alcoholic fatty liver disease 💬
 1件: LEPR 💬 D05014 💬 Metreleptin 1件: 265 💬
124 Non-alcoholic fatty liver disease 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
125 Non-alcoholic fatty liver disease 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
126 Non-alcoholic fatty liver disease 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
127 Non-alcoholic fatty liver disease 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
128 Olfactory transduction 💬
 2件: PDE1B, PDE2A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
129 Olfactory transduction 💬
 2件: PDE1B, PDE2A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
130 Oocyte meiosis 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
131 Osteoclast differentiation 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
132 Osteoclast differentiation 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
133 Osteoclast differentiation 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
134 Ovarian steroidogenesis 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
135 Oxytocin signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
136 Pancreatic cancer 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
137 Parathyroid hormone synthesis, secretion and action 💬
 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
138 Parathyroid hormone synthesis, secretion and action 💬
 4件: PDE4A, PDE4B, PDE4C, PDE4D 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
139 Parkinson disease 💬
 1件: ADORA2A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
140 Parkinson disease 💬
 1件: ADORA2A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
141 Pathways in cancer 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
142 Pathways in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
143 Pathways in cancer 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
144 Pathways in cancer 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
145 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
146 PI3K-Akt signaling pathway 💬
 1件: GHR 💬 D05394 💬 Pegvisomant 2件: 78, 265 💬
147 PI3K-Akt signaling pathway 💬
 2件: GHR, IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
148 PI3K-Akt signaling pathway 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
149 PI3K-Akt signaling pathway 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
150 PPAR signaling pathway 💬
 1件: APOC3 💬 D11648 💬 Volanesorsen 1件: 265 💬
151 PPAR signaling pathway 💬
 1件: PPARA 💬 D00565 💬 Fenofibrate 6件:  8 , 79, 93, 94, 97, 265 💬
152 PPAR signaling pathway 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
153 PPAR signaling pathway 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
154 Progesterone-mediated oocyte maturation 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
155 Progesterone-mediated oocyte maturation 💬
 1件: PDE3B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
156 Progesterone-mediated oocyte maturation 💬
 1件: PDE3B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
157 Prolactin signaling pathway 💬
 1件: JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
158 Prostate cancer 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
159 Proteoglycans in cancer 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
160 Purine metabolism 💬
 9件: PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
161 Purine metabolism 💬
 9件: PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
162 Rap1 signaling pathway 💬
 1件: ADORA2A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
163 Rap1 signaling pathway 💬
 1件: ADORA2A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
164 Rap1 signaling pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
165 Ras signaling pathway 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
166 Regulation of lipolysis in adipocytes 💬
 2件: ADORA1, PDE3B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
167 Regulation of lipolysis in adipocytes 💬
 2件: ADORA1, PDE3B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
168 Renin secretion 💬
 4件: ADORA1, PDE1B, PDE3A, PDE3B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
169 Renin secretion 💬
 4件: ADORA1, PDE1B, PDE3A, PDE3B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
170 Signaling pathways regulating pluripotency of stem cells 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
171 Signaling pathways regulating pluripotency of stem cells 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
172 Sphingolipid signaling pathway 💬
 1件: ADORA1 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
173 Sphingolipid signaling pathway 💬
 1件: ADORA1 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
174 Taste transduction 💬
 1件: PDE1B 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
175 Taste transduction 💬
 1件: PDE1B 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
176 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
177 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D08410 💬 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333 💬
178 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
179 Th1 and Th2 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
180 Th17 cell differentiation 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
181 Thermogenesis 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
182 Thermogenesis 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
183 Thermogenesis 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
184 Thyroid cancer 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
185 Thyroid cancer 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
186 Tight junction 💬
 2件: PRKAA1, PRKAA2 💬 D04966 💬 Metformin 25件:  2 ,  6 ,  8 , 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 218, 225, 233, 265, 285, 299, 301 💬
187 Toxoplasmosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
188 Transcriptional misregulation in cancer 💬
 1件: IGF1R 💬 D03297 💬 Mecasermin 6件: 65, 78, 96, 168, 265, 299 💬
189 Transcriptional misregulation in cancer 💬
 1件: PPARG 💬 D08378 💬 Pioglitazone 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
190 Transcriptional misregulation in cancer 💬
 1件: PPARG 💬 D08491 💬 Rosiglitazone 5件: 46, 75, 97, 222, 265 💬
191 Tuberculosis 💬
 2件: JAK1, JAK2 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬
192 Vascular smooth muscle contraction 💬
 1件: ADORA2A 💬 D00528 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
193 Vascular smooth muscle contraction 💬
 1件: ADORA2A 💬 D01453 💬 Caffeine 8件:  2 ,  6 , 21, 46, 78, 96, 97, 265 💬
194 Viral carcinogenesis 💬
 1件: JAK1 💬 D10308 💬 Baricitinib 13件:  2 , 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 💬

先頭へ